IPO - Autolus Therapeutics plc

Form Type: S-1

Filing Date: 2025-05-08

Corporate Action: Ipo

Type: New

Accession Number: 000119312525116059

Filing Summary: Autolus Therapeutics plc has filed a registration statement under the Securities Act of 1933 for the resale of up to 54,584,250 American Depositary Shares (ADSs) representing certain ordinary shares. This registration is aimed at fulfilling contractual obligations to selling securityholders identified within the document. It includes previously registered securities from prior registration statements. The offering will not result in proceeds to the company, as the selling securityholders will receive all net proceeds, while Autolus will bear the registration costs. The company has an FDA-approved product, AUCATZYL, launched in January 2025, and is pursuing additional regulatory approvals in Europe. The ADSs are traded under the symbol 'AUTL' on the Nasdaq Global Select Market. The prospectus highlights potential risks for investors, along with a detailed plan of distribution and use of proceeds.